

www.profertil.eu







European Urological Review CONTROLLED STUDY VARICOCELE STUDY PILOT STUDY

IMPROVING MALE FERTILITY





M. IMHOF, J. LACKNER, M. LIPOVAC, P. CHEDRAUI AND C. RIEDL

Controlled Study 2011


"Micronutrient supplementation increases sperm quality in the subfertile male."

In the context of this controlled comparative study an active treatment group was invited to take two capsules of PROfertil® daily for a period of 3 month between the first and the follow up semen analysis. Subfertile men receiving no active treatment served as controls.

All parameters evaluated by semen analysis significantly increased after 3 months of treatment:

25.76% PREGNANCIES

IN THE TREATMENT GROUP
AFTER SIX MONTHS
& NO ADVERSE EFFECTS



n 0

n 3

			CONTROL GROUP
Patients (205)		132	73
Inclusion		≥ 1 year of s	ubfertility
Criteria		and ≥ 2 seme	n analysis
Exclusion	Azoospermia, aspermia, varico-		
Criteria	cele, recent urogenital infections		

	, , , , , , , , , , , , , , , , , , , ,	,
Criteria cele, re	ecent urogenita	al infections
Ejaculatory		
Volume (ml)	+ 33.3%	+ 3.7%
Sperm Cell		
Density (mill/ml)	+ 215.5%	+ 46.4%
Progressive		
Motility (%)	+ 83.1%	+ 44.0%
Normal		
Morphology (%)	+ 23.0%	-2.4 %
Total		
Motility (%)	+ 36.4%	+ 33.9%

"Micronutrients as an alternative to fertility treatment in men with subclinical varicocele "1)



I. SCHAUER, R. JOST, M. IMHOF

Varicocele Study 2009


In the context of this study 51 men with subclinical varicocele (WHO classification 0.1). two pathological spermiogrames and an unfulfilled desire for a child took 2 capsules of PROfertil® daily for the duration of 3 months.

After a time period of 3 months a new semen analysis was performed.

41.18% **PREGNANCIES**


IN THE TREATMENT GROUP AFTER SIX MONTHS & NO ADVERSE EFFECTS


Patients (51)	51, ø 32 years (18-43)
Inclusion	Infertility > 2 years
Criteria	At least 2 pathological
	semen analysis
Exclusion	Infections, aspermia,
Criteria	hormonal disturbances




Ejaculatory Volume (ml)











Ejaculatory	
Volume (ml)	+ 15.57%
Sperm Cell	
Density (mill/ml)	+ 11.88%
Progressive	
Motility (%)	+ 43.72%
Normal	
Morphology (%)	+ 18.22%
Total	
Motility (%)	+ 15.99%

1) Source: Fortbildungstagung der österr. Gesellschaft für Urologie und Andrologie mit Jahreshauptversammlung der ÖGU Linz, Austria 2010; EAU Bratislava 2010



M. IMHOF

"The use of the nutraceutical PROfertil® – a therapy of the male factor"²⁾

Pilot Study 2006-2008


17.5% PREGNANCIES

IN THE TREATMENT GROUP
AFTER SIX MONTHS
& NO ADVERSE EFFECTS


The goal of this study was to administer a combination product comprising 8 substances, which are all known to improve semen quality. The hypothesis is that the effect of the single substances accumulate and therefore ensure a stronger response.

The patients took 2 capsules of PROfertil® a day for the duration of 3 months.

Ejaculatory Volume (ml)




Sperm Cell Density (mill/ml)



Progressive Motility (%)



Normal Morphology (%)



TREATMENT GROUP

Patients (120)	120, ø 35,9 years (23–58)
nclusion	Infertility > 2 years
Criteria	At least 2 pathological

semen analysis

Exclusion Varicocele, infections, aspermia,
Criteria hormonal disturbances

IMPROVEMENT IN % AFTER 3 MONTHS

=jacaiatoi j	
Volume (ml)	+ 24.05%
Sperm Cell	
Density (mill/ml)	+ 80.54%
Progressive	
Motility (%)	+ 115.30%
Normal	
Morphology (%)	+ 24.91%
Total	
Motility (%)	+ 48.71%

2) Source EAU Bratislava 2010

Lenus Pharma GesmbH Seeböckgasse 59, 1160 Vienna/Austria Phone: +43 1 405 14 19,Fax: +43 1 405 14 19-20 profertil@lenuspharma.com, www.lenuspharma.com